| pubmed-article:7559196 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7559196 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7559196 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7559196 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:7559196 | lifeskim:mentions | umls-concept:C0267924 | lld:lifeskim |
| pubmed-article:7559196 | lifeskim:mentions | umls-concept:C0008809 | lld:lifeskim |
| pubmed-article:7559196 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:7559196 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:7559196 | lifeskim:mentions | umls-concept:C0936233 | lld:lifeskim |
| pubmed-article:7559196 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:7559196 | pubmed:dateCreated | 1995-11-14 | lld:pubmed |
| pubmed-article:7559196 | pubmed:abstractText | One hundred consecutive patients with acute suppurative cholangitis were randomized in a prospective, controlled clinical trial to receive either ciprofloxacin (200 mg bd iv) or triple therapy comprising ceftazidime (1 g bd iv), ampicillin (500 mg qds iv) and metronidazole (500 mg tds iv); 46 and 44 patients in the ciprofloxacin and triple therapy groups respectively were suitable for inclusion in the analysis of efficacy. In two-thirds of the patients biliary obstruction was caused by ductal calculi and in one-third by malignant or benign strictures of the biliary tract. Bacteraemia was documented in 38% of patients in the ciprofloxacin group and in 34% of patients in the triple therapy group, while bile cultures were positive in 87% and 92% of patients in the ciprofloxacin and triple therapy groups respectively. Escherichia coli, Klebsiella spp. and Enterococcus spp. were the most common biliary isolates. Eighty-five per cent of evaluable patients in the ciprofloxacin group and 77% of those in the triple therapy group responded to therapy. The mean durations of fever, septicaemic shock and hospitalization were also similar in the two treatment groups. Six (13%) patients in the ciprofloxacin group and seven (16%) in the triple therapy group required urgent endoscopy or surgery for uncontrolled infection. Recurrence of fever after an initial response was documented in one (2%) patient receiving ciprofloxacin and in three (7%) patients receiving triple therapy. The incidences of mortality were 4% in the ciprofloxacin group and 2% in the triple therapy group. The results of this study suggest that ciprofloxacin alone is adequate empirical therapy for patients with cholangitis. | lld:pubmed |
| pubmed-article:7559196 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7559196 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7559196 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7559196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7559196 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7559196 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:7559196 | pubmed:issn | 0305-7453 | lld:pubmed |
| pubmed-article:7559196 | pubmed:author | pubmed-author:LiA KAK | lld:pubmed |
| pubmed-article:7559196 | pubmed:author | pubmed-author:ChungS CSC | lld:pubmed |
| pubmed-article:7559196 | pubmed:author | pubmed-author:LeungJ WJW | lld:pubmed |
| pubmed-article:7559196 | pubmed:author | pubmed-author:ChengA FAF | lld:pubmed |
| pubmed-article:7559196 | pubmed:author | pubmed-author:SungJ JJJ | lld:pubmed |
| pubmed-article:7559196 | pubmed:author | pubmed-author:SuenRR | lld:pubmed |
| pubmed-article:7559196 | pubmed:author | pubmed-author:LyonD JDJ | lld:pubmed |
| pubmed-article:7559196 | pubmed:author | pubmed-author:CoA LAL | lld:pubmed |
| pubmed-article:7559196 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7559196 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:7559196 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7559196 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7559196 | pubmed:pagination | 855-64 | lld:pubmed |
| pubmed-article:7559196 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:meshHeading | pubmed-meshheading:7559196-... | lld:pubmed |
| pubmed-article:7559196 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7559196 | pubmed:articleTitle | Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial. | lld:pubmed |
| pubmed-article:7559196 | pubmed:affiliation | Department of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong. | lld:pubmed |
| pubmed-article:7559196 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7559196 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7559196 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7559196 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7559196 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7559196 | lld:pubmed |
